

Otitis media with effusion in under 12s

[I] Evidence reviews for auto-inflation for children with otitis media with effusion (OME)

NICE guideline number tbc

Evidence reviews underpinning recommendation 1.5.1 in the NICE guideline

March 2023

Draft for consultation

This evidence review was developed by NICE

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).

ISBN:

Contents

Auto-inflation for children with otitis media with effusion (OME)	6
Review question	6
Introduction	6
Summary of the protocol	6
Methods and process	8
Effectiveness evidence.....	8
Summary of included studies.....	9
Summary of the evidence.....	9
Economic evidence	10
Summary of included economic evidence.....	10
Economic model.....	11
Unit costs	11
The committee’s discussion and interpretation of the evidence	11
Recommendations supported by this evidence review	13
References – included studies.....	14
Appendices	15
Appendix A Review protocols	15
Review protocol for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	15
Appendix B Literature search strategies	16
Literature search strategies for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?.....	16
Appendix C Effectiveness evidence study selection	19
Study selection for: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	19
Appendix D Characteristics of studies tables	20
Characteristics of studies tables for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?.....	20
Appendix E Data and analyses tables	21
Data and analyses tables for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?.....	21
Appendix F Summary of findings tables	22
Summary of findings tables for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?.....	22
Appendix G Economic evidence study selection	23

	Study selection for: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	23
Appendix H	Economic evidence tables	24
	Economic evidence tables for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	24
Appendix I	Economic model	26
	Economic model for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	26
Appendix J	Excluded studies	27
	Excluded studies for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	27
Appendix K	Research recommendations – full details	28
	Research recommendations for review question: What is the effectiveness of auto-inflation for managing OME with associated hearing loss in children under 12 years?	28

1 Auto-inflation for children with otitis media 2 with effusion (OME)

3 Review question

4 What is the effectiveness of auto-inflation for managing OME with associated hearing loss in
5 children under 12 years?

6 Introduction

7 The aim of this review is to assess the effectiveness of auto-inflation in managing OME with
8 associated hearing loss in children under 12 years.

9 At the start of development, the term ventilation tube (VT) was used to refer to tubes inserted
10 during surgery for OME. However, the committee later agreed that the term grommet should
11 be used instead as this is likely to be the term that is more familiar to readers of the guideline
12 and would avoid confusion with tubes used to assist with breathing. Therefore, both terms
13 appear in this evidence review.

14 Summary of the protocol

15 See Table 1 for a summary of the Population, Intervention, Comparison and Outcome
16 (PICO) characteristics of this review.

17 Table 1: Summary of the protocol (PICO table)

Population	Inclusion: Children aged 6 months to 12 years with unilateral or bilateral otitis media with effusion (OME). <ul style="list-style-type: none">• If a study includes children aged younger than 6 months and older than 12 years, we will only include the study if the majority of children fit our inclusion criteria or only if the trialists present outcome data by age group.• Include all children regardless of any comorbidity such as Down syndrome or cleft palate <p>Clinical diagnosis of OME will be confirmed by oto(micro)scopy and/or tympanometry</p>
Intervention	Auto-inflation by any method
Comparison	<ul style="list-style-type: none">• Auto-inflation versus watchful waiting• Auto-inflation versus non-surgical (medical only) treatment• Auto-inflation versus grommet <p>If trial participants have received other treatments, for example, intranasal steroids, oral steroids, antibiotics, mucolytics, or decongestants, the Cochrane group will include these trials if both arms of the study received identical treatments.</p>

Outcome

We will analyse the following outcomes in the review, but we will not use them as a basis for including or excluding studies. We will assess all outcomes in the very short term (< 6 weeks for postoperative adverse events), short term (<= 3 months), medium term (> 3 months to <= 1 year) and long term (> 1 year).

Critical

- Hearing
 - proportion of children whose hearing has returned to normal;
 - mean final hearing threshold (determined for the child or ear, depending on the unit of analysis);
 - change in hearing threshold from baseline (determined for the child or ear, depending on the unit of analysis).
- Disease-specific quality of life measured using a validated instrument, for example:
 - OM8-30;
 - Otitis Media-6.
- Adverse events: Pain and distress caused by the procedure.

Important

- Presence/persistence of OME
- Adverse events - measured by the number of participants affected.
 - eardrum perforation
 - middle ear infection
 - otalgia
 - Acute otitis media (AOM)
- Compliance
- Receptive language skills, measured using a validated scale, for example:
 - Peabody Picture Vocabulary Test – Revised;
 - Reynell Developmental Language Scales (relevant domains);
 - Preschool Language Scale (PLS) (relevant domains);
 - Sequenced Inventory of Communication (SCID) (relevant domains).
- Speech development or expressive language skills, measured using a validated scale, for example:
 - Schlichting test;
 - Lexi list;
 - Reynell Developmental Language Scales (relevant domains);
 - PLS (relevant domains);
 - SCID (relevant domains).
- Cognitive development, measured using a validated scale, for example:
 - Griffiths Mental Development Scales;
 - McCarthy General Cognitive Index;
 - Bayley Scales of Infant and Toddler Development.
- Psychosocial outcomes, measured using a validated scale, for example:
 - Social Skills Scale of the Social Skills Rating System;
 - Child behaviour Checklist;
 - Strengths and Difficulties Questionnaire;
 - Pediatric Symptom Checklist.
- Listening skills, for example, listening to stories and instructions effectively. Given that there are few validated scales to assess listening skills in children with OME, we will include any methods used by trialists.
- Generic health-related quality of life assessed using a validated instrument, for example:
 - EQ-5D;

- TNO AZL Children's QoL (TACQOL);
- TNO AZL Pre-school children QoL (TAPQOL);
- TNO AZL Infant Quality of Life (TAIQOL);
- Infant Toddler Quality of Life Questionnaire (ITQOL);
- Child Health Questionnaire (CHQ).
- Parental stress, measured using a validated scale, for example:
 - Parenting Stress Index.
- Vestibular function
 - balance;
 - coordination.
- Number of doctor-diagnosed AOM episodes within a specified time frame

1 AOM: acute otitis media; CHQ: Child Health Questionnaire; EQ: EuroQol; ITQOL: Infant Toddler Quality of Life;
 2 OM: otitis media; OME: otitis media with effusion; PLS: Preschool Language Scale; QoL: quality of life; SCID:
 3 Sequenced Inventory of Communication; TACQOL: TNO AZL Children's Quality of Life Questionnaire; TAIQOL:
 4 TNO AZL Infant Quality of Life; TAPQOL: TNO AZL Pre-school children's Quality of Life questionnaire; TNO AZL:
 5 Netherlands Organisation for Applied Scientific Research Academic Medical Centre

6 For further details see the review protocol in appendix A.

7 Methods and process

8 During the development of this guideline, a registered Cochrane protocol was identified
 9 which matched the committee's intended PICO's.

10 The Cochrane review team completed a review investigating the effectiveness of auto-
 11 inflation for OME in children (Webster 2023) during guideline development and presented
 12 their results to the committee, who used them to make recommendations. Cochrane's
 13 methods are closely aligned to standard NICE methods, minor deviations (defining primary
 14 and secondary outcomes as opposed to critical and important, assessing the risk of bias in
 15 primary studies using version 1 (as opposed to version 2) of the Cochrane Risk of Bias tool,
 16 how clinically important differences are determined, and including countries from a broader
 17 range of income categories than the majority of the other reviews in the guideline) relevant to
 18 the topic area were highlighted to the committee and taken into account in discussions of the
 19 evidence. Full details of the Cochrane review, including methods, are available in the review
 20 of auto-inflation for children with OME, Webster 2023 at
 21 <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

22 We thank the Cochrane ENT Group for their assistance in providing the literature searches
 23 and data for review questions relating to Otitis media with effusion in under 12s.

24 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

25 Effectiveness evidence

26 Included studies

27 A Cochrane review (Webster 2023) including 12 randomised controlled trials (Arick 2005;
 28 Banigo 2016; Bidarian-Moniri 2014; Blanshard 1993; Brooker 1992; Chan 1989; Ercan 2005;
 29 Heaf 1991; Scadding 2014; Stangerup 1992; Williamson 2015a; Williamson 2015b) is
 30 considered in this report. This review was used for making recommendations by the
 31 committee, as it was considered sufficiently relevant, high quality and up to date.

32 Two studies included children with air-conduction thresholds of 20 dBHL and over (Arick
 33 2005; Bidarian-Moniri 2014), 2 studies included children with air-conduction thresholds of 25
 34 dBHL and over (Banigo 2016; Heaf 1991), and 8 studies did not report data on levels of
 35 hearing loss (Blanshard 1993; Brooker 1992; Chan 1989; Ercan 2005; Scadding 2014;
 36 Stangerup 1992; Williamson 2015a; Williamson 2015b).

- 1 Seven studies included children aged up to 6 years (Banigo 2016; Bidarian-Moniri 2014;
2 Blanshard 1993; Brooker 1992; Scadding 2014; Stangerup 1992; Williamson 2015a), 1 study
3 included children aged 3 to 18 years (Chan 1989), 1 study included children aged 4 to 11
4 years (Williamson 2015b), 1 study included children aged over 6 years (Ercan 2005), and 2
5 studies did not report ages of participants (Arick 2005; Heaf 1991).
- 6 Eleven studies used auto-inflation devices (Arick 2005; Banigo 2016; Bidarian-Moniri 2014;
7 Blanshard 1993; Brooker 1992; Chan 1989; Ercan 2005; Scadding 2014; Stangerup 1992;
8 Williamson 2015a; Williamson 2015b), but in 1 study children were asked to blow their nose
9 without using auto-inflation devices (Heaf 1991).
- 10 The Cochrane review is summarised in Table 2.
- 11 See the Cochrane review for the literature search strategies and study selection flow charts,
12 Webster 2023 at <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

13 Excluded studies

- 14 See the lists of excluded studies in the Cochrane review with reasons for their exclusions,
15 Webster 2023 at <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

16 Summary of included studies

- 17 Summaries of the studies that were included in this review are presented in Table 2.

18 **Table 2: Summary of included studies.**

Study	Population	Comparison	Outcomes
Webster 2023 Systematic review UK	Children aged 2 years to 12 years with unilateral or bilateral otitis media with effusion for a duration of at least one month. Number of studies: 12 Number of participants: 1117	Auto-inflation versus watchful waiting (no treatment) 12 trials (Arick 2005; Banigo 2016; Bidarian-Moniri 2014; Blanshard 1993; Brooker 1992; Chan 1989; Ercan 2005; Heaf 1991; Scadding 2014; Stangerup 1992; Williamson 2015a; Williamson 2015b)	Primary: <ul style="list-style-type: none"> Hearing as <ul style="list-style-type: none"> (i) return to normal (ii) mean threshold Disease-specific quality of life Secondary: <ul style="list-style-type: none"> Presence/Persistence of OME Adverse events: Otagia Number of doctor-diagnosed AOM episodes

19 *AOM: acute otitis media; OME: otitis media with effusion*

- 20 See the Cochrane review for characteristics of studies tables and forest plots, Webster 2023
21 at <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

22 Summary of the evidence

- 23 The Cochrane review of auto-inflation for children with OME investigated 1 comparison, with
24 the following findings:

- 25 • Auto-inflation versus watchful waiting (no treatment): hearing
26 Auto-inflation had an important benefit in terms of hearing returned to normal in the
27 very short-term (<6 weeks) compared with watchful waiting, but the certainty of the
28 evidence was very low. In terms of hearing returned to normal in the short-term (>6
29 weeks to ≤3 months), one study (Arick 2005) showed that auto-inflation had an
30 important benefit, but one study (Heaf 1991) did not. The inconsistency in the

1 effectiveness of intervention between these two studies may be due to the use of
2 different auto-inflation methods. Auto-inflation improved hearing threshold (at 1 kHz
3 and 4 kHz frequencies) in the short-term compared with watchful waiting (no
4 treatment). There was no evidence of important differences between auto-inflation
5 and watchful waiting for hearing returned to normal in the long-term (>12 months),
6 hearing threshold (at 0.5 kHz and 2 kHz frequencies) in the short-term and hearing
7 threshold in the very short-term. The certainty of the evidence was low to very low for
8 these outcomes.

- 9 • Auto-inflation versus watchful waiting (no treatment): disease specific quality of life,
10 presence/persistence of OME, otalgia, and number of doctor-diagnosed AOM
11 Auto-inflation had an important benefit in terms of disease specific quality of life in the
12 short-term compared with watchful waiting. There was no evidence of important
13 differences between auto-inflation and watchful waiting for presence/persistence of
14 OME in the very short-term and short-term, otalgia, and number of doctor-diagnosed
15 AOM episodes in the short-term. The certainty of the evidence was low to very low for
16 these outcomes, and no evidence was available for any of the other outcomes
17 specified in the protocol.

18 There were two comparisons in the Cochrane review protocol that were not reported on by
19 any studies: auto-inflation versus non-surgical (medical only) treatment, and auto-inflation
20 versus grommet.

21 See the Cochrane review) for summary of findings tables and full results, including all
22 primary and secondary outcomes and sub-group analyses, Webster 2023 at
23 <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

24 Economic evidence

25 Included studies

26 A global health economic search was undertaken, independently of the Cochrane review, to
27 cover all the review questions considered in this guideline. One economic study was
28 identified which was relevant to this question (Williamson 2015).

29 Excluded studies

30 Economic studies not included in this review are listed, and reasons for their exclusion are
31 provided in appendix K.

32 Summary of included economic evidence

33 See Table 3 for the economic evidence profile of the included study.

34 **Table 3: Economic evidence profile of a systematic review of economic evaluations**
35 **for auto-inflation for managing OME with associated hearing loss in children**
36 **under 12 years**

Study	Limitations	Applicability	Other comments	Incremental			Uncertainty
				Costs	Effect	Cost effectiveness	
Williamson 2015 Nasal balloon auto inflation	Minor limitations ¹	Partially applicable ²	Economic evaluation alongside a randomised controlled trial	£14	0.003 QALYs	£8,463 per QALY gained	Probabilistic sensitivity analysis suggested there was a 50.1% chance that

Study	Limitations	Applicability	Other comments	Incremental			Uncertainty
				Costs	Effect	Cost effectiveness	
n plus standard care versus standard care							nasal auto inflation was cost-effective as a cost-effectiveness threshold of £20,000 per QALY

1 QALYS =Quality adjusted life years

2 ¹ A 3 month time horizon for outcomes may not have captured all the benefits of the intervention

3 ² NICE reference case was not followed for the elicitation of QALY values

4 Economic model

5 No economic modelling was undertaken for this review because the committee agreed that
6 other topics were higher priorities for economic evaluation as the intervention under review
7 was considered low cost.

8 Unit costs

9

Resource	Unit costs	Source
Auto inflation device	£6.69	NHS Drugs Tariff December 2022

10 The committee's discussion and interpretation of the evidence

11 The outcomes that matter most

12 The primary outcomes were hearing, disease-specific quality of life, and pain and distress
13 associated with the procedure. The committee agreed these outcomes were critical: hearing
14 loss is often associated with OME, and this could impact on the child's development and
15 measuring hearing would be a direct measure of any differential effectiveness associated
16 with auto-inflation; disease-specific quality of life is a global measure of wellbeing that takes
17 into account both beneficial and adverse effects of the interventions; and auto-inflation may
18 have adverse events associated with it, the most likely being pain and distress caused by
19 procedure.

20 All other outcomes listed in the protocol (presence or persistence of OME, adverse events
21 (other than pain and distress), compliance, receptive language skills, speech development or
22 expressive language skills, cognitive development, psychosocial outcomes, listening skills,
23 generic health-related quality of life, parental stress, vestibular function and number of
24 doctor-diagnosed acute otitis media (AOM) episodes were agreed to be important outcomes
25 by the committee. Presence or persistence of OME after auto-inflation can directly indicate
26 the effectiveness of the intervention, and adverse events other than pain and distress
27 (including ear drum perforation, middle ear infection, otalgia, and acute otitis media), that
28 may be relatively common with auto-inflation, are important to measure because they
29 capture risks associated with the intervention. The committee were aware that some children
30 may not engage or may not be able to use auto-inflation device; therefore, compliance with
31 auto-inflation was selected as important outcome as it can influence the effectiveness of the
32 intervention. OME can be associated with impairment of receptive and expressive language
33 skills, cognitive development, psychological outcomes, listening skills, and vestibular
34 function, which could impact on the child's development and quality of life. Therefore, these

1 were selected as important outcomes. The committee agreed that generic health-related
2 quality of life was important because this would measure the well-being of the child more
3 generally than disease-specific scales. The parents of children who have OME may have
4 high level of stress, and thus parental stress was selected as an important outcome to see if
5 auto-inflation can help reduce this stress. Number of doctor-diagnosed AOM episodes was
6 also selected as an important outcome because auto-inflation may have a protective role for
7 recurrent AOM.

8 **The quality of the evidence**

9 The quality of the evidence was assessed using GRADE methodology, and the evidence for
10 all outcomes identified in this review was low to very low quality because of high or moderate
11 risk of bias assessed using version 1 of the Cochrane RoB tool, serious or very serious
12 heterogeneity and imprecision, and the inclusion of indirect interventions (such as nose-
13 blowing and facemasks rather than use of an auto-inflation device).

14 **Benefits and harms**

15 The evidence showed that auto-inflation improved hearing in the very short-term (<6 weeks)
16 and short-term (>6 weeks to ≤3 months) when reported as a proportion of children whose
17 hearing has returned to normal and change in hearing threshold from baseline, respectively,
18 compared with no treatment. However, there was no evidence of important differences in the
19 proportion of children whose hearing has returned to normal in the long term (>12 months) as
20 a result of auto-inflation, and there was inconsistency between studies regarding whether
21 there was an important difference in the proportion of children whose hearing returned to
22 normal in the short term (>6 weeks to ≤3 months), with one study showing higher rates of
23 hearing returned to normal and one study showing no evidence of an important difference.
24 The evidence showed that auto-inflation improved disease-specific quality of life (short term).
25 There was no evidence of important differences in the following outcomes between the auto-
26 inflation and no treatment groups: rates of persistence of OME (very short term and short
27 term), episodes of acute otitis media (short term) and adverse events (otalgia). However, the
28 quality of evidence was low to very low. Therefore, the committee made a recommendation
29 based on the best available evidence, current practice and their knowledge and experience.
30 The committee acknowledged that hearing is the most important outcome in children with
31 OME, and that auto-inflation may improve hearing in the very-short term and short-term. The
32 committee agreed the critical period to consider for hearing outcomes is in the short-term,
33 because a negative impact on hearing levels even for short periods of time can significantly
34 impact a child's development, and it is therefore important to negate these as soon as
35 possible rather than waiting for spontaneous resolution. Therefore, the committee agreed
36 that auto-inflation may have important benefits for children in the short term, and
37 consequently may reduce the requirement of further active interventions. However, the
38 committee were aware that some children, especially very young children, may not engage
39 with or may not be able to use the device. They also acknowledged that children should use
40 auto-inflation devices three times a day, and those attending preschool or school may not
41 have the opportunity to do so. Therefore, they agreed that auto-inflation should be
42 considered in children who can engage with the intervention. The committee noted that this
43 recommendation would be in line with current practice.

44 **Cost effectiveness and resource use**

45 The committee were aware of one study (Williamson 2015) which reported an incremental
46 cost-effectiveness ratio of £8,463 per QALY which would be considered cost-effective at a
47 cost-effectiveness threshold of £20,000 per QALY. The committee noted that there was
48 considerable uncertainty around this result with a probabilistic sensitivity analysis reporting
49 that auto-inflation had a 50.1% probability of being cost-effective at a cost-effectiveness
50 threshold of £20,000 per QALY. Although, the additional costs of the intervention including

1 training were small at £14, they were statistically significant. The QALY gain reported for
2 auto-inflation did not reach statistical significance although the committee noted that the
3 QALY gain was in the same direction as the trial's primary outcome, namely tympanometric
4 resolution of type B effusions. Therefore, the committee concluded there was weak economic
5 evidence to support the use of auto-inflation and they recommended that it could be
6 considered in children who are able to engage with the treatment. The committee did not
7 believe this recommendation would have a significant resource impact as it already reflects
8 practice in some areas and is not an expensive intervention.

9 **Recommendations supported by this evidence review**

10 This evidence review supports recommendation 1.5.1.

11

1 **References – included studies**

2 **Effectiveness**

3 **Webster 2023**

4 Webster KE, Mulvaney CA, Galbraith K, Rana M, Marom T, Daniel M, Venekamp RP,
5 Schilder AGM, MacKeith S. Autoinflation for otitis media with effusion (OME) in children.
6 Cochrane Database of Systematic Reviews 2023. Art. No.: CD015253. DOI:
7 10.1002/14651858.CD015253.pub2

8 **Williamson 2018**

9 Williamson I, Vennik J, Harnden A, Voysey M, Perera R, Breen M, et al. An open randomised
10 study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in
11 primary care. *Health Technol Assess* 2015;19(72)

12

1 Appendices

2 Appendix A Review protocols

3 Review protocol for review question: What is the effectiveness of auto-inflation for managing OME with associated 4 hearing loss in children under 12 years?

5 See the Cochrane review protocol, Webster 2023 at <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

6

1 Appendix B Literature search strategies

2 Literature search strategies for review question: What is the effectiveness of 3 auto-inflation for managing OME with associated hearing loss in children under 4 12 years?

5 Clinical search

6 See Appendix 1 and Appendix 2 of the Cochrane review, Webster 2023 at
7 <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

8 Economic literature search strategy

9 A global, population-based search was undertaken to find economic evidence covering all
10 parts of the guideline.

11 Database: MEDLINE – OVID interface

12 Date last searched: 09/11/2022

#	Searches
1	otitis media with effusion/
2	(glue ear or ((middle ear or otitis media) adj2 effusion*) or ome or ((secretory or serous) adj2 otitis media)).ti,ab.
3	1 or 2
4	Economics/
5	Value of life/
6	exp "Costs and Cost Analysis"/
7	exp Economics, Hospital/
8	exp Economics, Medical/
9	Economics, Nursing/
10	Economics, Pharmaceutical/
11	exp "Fees and Charges"/
12	exp Budgets/
13	budget*.ti,ab.
14	cost*.ti.
15	(economic* or pharmaco?economic*).ti.
16	(price* or pricing*).ti,ab.
17	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
18	(financ* or fee or fees).ti,ab.
19	(value adj2 (money or monetary)).ti,ab.
20	or/4-19
21	exp models, economic/
22	*Models, Theoretical/
23	*Models, Organizational/
24	markov chains/
25	monte carlo method/
26	exp Decision Theory/
27	(markov* or monte carlo).ti,ab.
28	econom* model*.ti,ab.
29	(decision* adj2 (tree* or analy* or model*)).ti,ab.
30	or/21-29
31	20 or 30
32	3 and 31
33	(animals/ not humans/) or exp animals, laboratory/ or exp animal experimentation/ or exp models, animal/ or exp rodentia/ or (rat or rats or mouse or mice).ti.
34	32 not 33
35	limit 34 to english language
36	limit 35 to yr="2000 -Current"

13 Database: Embase – OVID interface

14 Date last searched: 09/11/2022

#	Searches
1	exp secretory otitis media/
2	(glue ear or ((middle ear or otitis media) adj2 effusion*) or ome or ((secretory or serous) adj2 otitis media)).ti,ab.
3	1 or 2

#	Searches
4	health economics/
5	exp economic evaluation/
6	exp health care cost/
7	exp fee/
8	budget/
9	funding/
10	budget*.ti,ab.
11	cost*.ti.
12	(economic* or pharmaco?economic*).ti.
13	(price* or pricing*).ti,ab.
14	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)):ab.
15	(financ* or fee or fees).ti,ab.
16	(value adj2 (money or monetary)).ti,ab.
17	or/4-16
18	statistical model/
19	exp economic aspect/
20	18 and 19
21	*theoretical model/
22	*nonbiological model/
23	stochastic model/
24	decision theory/
25	decision tree/
26	monte carlo method/
27	(markov* or monte carlo).ti,ab.
28	econom* model*.ti,ab.
29	(decision* adj2 (tree* or analy* or model*)):ti,ab.
30	or/20-29
31	17 or 30
32	3 and 31
33	(animal/ not human/) or nonhuman/ or exp animal experiment/ or exp experimental animal/ or animal model/ or exp rodent/ or (rat or rats or mouse or mice).ti.
34	32 not 33
35	limit 34 to english language
36	limit 35 to yr="2000 -Current"

1 Database: Cochrane Central Register of Controlled Trials (CENTRAL) – Wiley interface

2 Date last searched: 09/11/2022

ID	Search
#1	MeSH descriptor: [Otitis Media with Effusion] this term only
#2	((("glue ear" or ("middle ear" or "otitis media") near/2 effusion*) or ome or ((secretory or serious) near/2 "otitis media"))):ti,ab,kw
#3	#1 or #2
#4	MeSH descriptor: [Economics] this term only
#5	MeSH descriptor: [Value of Life] this term only
#6	MeSH descriptor: [Costs and Cost Analysis] explode all trees
#7	MeSH descriptor: [Economics, Hospital] explode all trees
#8	MeSH descriptor: [Economics, Medical] explode all trees
#9	MeSH descriptor: [Economics, Nursing] this term only
#10	MeSH descriptor: [Economics, Pharmaceutical] this term only
#11	MeSH descriptor: [Fees and Charges] explode all trees
#12	MeSH descriptor: [Budgets] explode all trees
#13	budget*.ti,ab
#14	cost*.ti
#15	(economic* or pharmaco?economic*):ti
#16	(price* or pricing*):ti,ab
#17	(cost* near/2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)):ab
#18	(financ* or fee or fees):ti,ab
#19	(value near/2 (money or monetary)):ti,ab
#20	{or #4-#19}
#21	MeSH descriptor: [Models, Economic] explode all trees
#22	MeSH descriptor: [Models, Theoretical] this term only
#23	MeSH descriptor: [Models, Organizational] this term only
#24	MeSH descriptor: [Markov Chains] this term only
#25	MeSH descriptor: [Monte Carlo Method] this term only
#26	MeSH descriptor: [Decision Theory] explode all trees
#27	(markov* or "monte carlo"):ti,ab
#28	(econom* next model*):ti,ab

ID	Search
#29	(decision* near/2 (tree* or analy* or model*)):ti,ab
#30	{or #21-#29}
#31	#20 or #30
#32	#3 and #31 with Cochrane Library publication date Between Jan 2000 and Apr 2022

1 **Database: International Network of Agencies for Health Technology Assessment
 2 (INAHTA)**

3 Date last searched: 09/11/2022

#	Searches
1	((("Otitis Media with Effusion"[mhe]) OR (((("glue ear" or (("middle ear" or "otitis media") and effusion*) or ome or ((secretory or serous) and "otitis media")))))
2	1 and FROM 2000 TO 2022 AND (English)[Language]

4 **Database: NHS Economic Evaluation Database (NHS EED) – CRD interface**

5 Date last searched: 09/11/2022

Line	Search for
1	MeSH DESCRIPTOR Otitis Media with Effusion EXPLODE ALL TREES
2	((glue ear or ((middle ear or otitis media) and effusion*) or ome or ((secretory or serous) and otitis media))) IN NHS EED
3	#1 OR #2

6

7

1 **Appendix C Effectiveness evidence study selection**

2 **Study selection for: What is the effectiveness of auto-inflation for managing**
3 **OME with associated hearing loss in children under 12 years?**

4 **Clinical search**

5 See Results of the search – figure 1 from the Cochrane review, Webster 2023 at
6 <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

7

8

9

10

1 **Appendix D Characteristics of studies tables**

2 **Characteristics of studies tables for review question: What is the effectiveness of auto-inflation for managing OME with** 3 **associated hearing loss in children under 12 years?**

4 See the Characteristics of included studies tables from the Cochrane review, Webster 2023 at
5 <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

6

7

1 **Appendix E Data and analyses tables**

2 **Data and analyses tables for review question: What is the effectiveness of auto-inflation for managing OME with associated** 3 **hearing loss in children under 12 years?**

4 See the Data and analyses tables from the Cochrane review, Webster 2023 at [https://www.nice.org.uk/guidance/indevelopment/gid-
5 ng10193/documents](https://www.nice.org.uk/guidance/indevelopment/gid-
5 ng10193/documents).

6
7

1 **Appendix F Summary of findings tables**

2 **Summary of findings tables for review question: What is the effectiveness of auto-inflation for managing OME with** 3 **associated hearing loss in children under 12 years?**

4 See the Summary of findings tables from the Cochrane review, Webster 2023 at [https://www.nice.org.uk/guidance/indevelopment/gid-
5 ng10193/documents](https://www.nice.org.uk/guidance/indevelopment/gid-
5 ng10193/documents).


6

1 Appendix G Economic evidence study selection

2 Study selection for: What is the effectiveness of auto-inflation for managing 3 OME with associated hearing loss in children under 12 years?

4 A global search was undertaken to cover all the review questions considered in this
5 guideline, and 1 study was identified which was applicable to this review question (see
6 Figure 1).

Figure 1: Study selection flow chart



7
8
9
10
11

1 Appendix H Economic evidence tables

2 Economic evidence tables for review question: What is the effectiveness of 3 auto-inflation for managing OME with associated hearing loss in children under 4 12 years?

5 **Table 4: Economic evidence tables for auto-inflation for managing OME with**
6 **associated hearing loss in children under 12 years**

Study country and type	Intervention and comparator	Study population, design and data sources	Costs and outcomes (descriptions and values)	Results	Comments
<p>Author and year: Williamson 2015</p> <p>Country: UK</p> <p>Type of economic analysis: Cost utility analysis</p> <p>Source of funding: Heath Technology Assessment programme of the National Institute for Health Research</p>	<p>Intervention: 160 children in a primary care setting randomised to nasal balloon auto inflation (Otovent) plus standard care three times a day for 1-3 months for the treatment of OME</p> <p>Comparator: 160 children in a primary care setting randomised to standard care</p>	<p>Population characteristics: School children aged 4-11 years with a history of OME in the previous 3 months and a type B tympanogram indicating a diagnosis of middle ear effusion</p> <p>Modelling approach/alongside an RCT: Economic evaluation alongside an RCT</p> <p>Source of baseline data: Standard care arm in RCT</p> <p>Source of effectiveness data: Intervention arm in RCT</p> <p>Source of cost data:</p>	<p>Mean cost per participant:</p> <p><i>Auto inflation:</i> £31.94 (95% CI: £24.20 to £39.90)</p> <p><i>Standard care:</i> £17.61 (95% CI: £10.50 to £24.90)</p> <p><i>Difference:</i> £14.33 (95% CI: £3.50 to £25.20)</p> <p>Primary measure of outcome: QALYs Quality of life was estimated using self-completed HUI3 questionnaires</p> <p>Mean QALY per participant:</p> <p><i>Auto inflation:</i> 0.200 QALYs (95% CI: 0.192 to 0.208)</p>	<p>ICERs: £8,463 per QALY (95% CI: -£104,894 to £121,820)</p> <p>Probability of being cost effective: 50.1% at a cost-effectiveness threshold of £20,000 per QALY</p>	<p>Perspective: NHS and a Personal Social Services perspective</p> <p>Currency: GBP</p> <p>Cost year: Not explicitly stated but costs sourced from 2012-2014 data</p> <p>Time horizon: 3 months</p> <p>Discounting: N/A</p> <p>Applicability: Directly applicable</p> <p>Limitations: Minor limitations</p> <p>Other comments: Time horizon may have been too short to capture differences in outcomes</p>

Study country and type	Intervention and comparator	Study population, design and data sources	Costs and outcomes (descriptions and values)	Results	Comments
		Resource use data was collected as part of the trial by searching electronic records Source of unit cost data: BNF September 2012, PSSRU 2011-12; NHS Reference Costs 2013; Primary Care Foundation 2013; Company supplying Otovent to NHS	<i>Standard care:</i> 0.197 QALYs (95% CI: 0.191 to 0.209) <i>Difference:</i> 0..003 QALYs (95% CI: -0.010 to 0.020)		

1 BNF = British National Formulary; CI = Confidence interval; GBP = Great British Pound; HUI = Health Utilities
 2 Index; ICER = Incremental cost-effectiveness ratio; OME = Otitis media with effusion; PSSRU = Personal and
 3 Social Services Research Unit; QALYs = Quality adjusted life years; RCT = Randomised control trial;

4
 5
 6

1 **Appendix I Economic model**

2 **Economic model for review question: What is the effectiveness of auto-**
3 **inflation for managing OME with associated hearing loss in children under 12**
4 **years?**

5 No economic analysis was conducted for this review question.

6

7

8

1 **Appendix J Excluded studies**

2 **Excluded studies for review question: What is the effectiveness of auto-**
3 **inflation for managing OME with associated hearing loss in children under 12**
4 **years?**

5 **Excluded effectiveness studies**

6 See the Characteristics of excluded studies table from the Cochrane review, Webster 2023
7 at <https://www.nice.org.uk/guidance/indevelopment/gid-ng10193/documents>.

8 **Excluded economic studies**

9 No economic evidence was excluded that related to this review.

10

11

1 **Appendix K Research recommendations – full details**

2 **Research recommendations for review question: What is the effectiveness of**
3 **auto-inflation for managing OME with associated hearing loss in children under**
4 **12 years?**

5 No research recommendations were made for this review question.

6